Get the Stockscreener App
76.55
1.57%
1.18
After Hours:
76.75
0.20
+0.26%
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $76.55, with a volume of 1.79M.
It is up +1.57% in the last 24 hours and down -4.28% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$75.37
Open:
$75.47
24h Volume:
1.79M
Relative Volume:
0.90
Market Cap:
$37.26B
Revenue:
$10.03B
Net Income/Loss:
$1.07B
P/E Ratio:
35.52
EPS:
2.1549
Net Cash Flow:
$1.39B
1W Performance:
+1.92%
1M Performance:
-4.28%
6M Performance:
-7.64%
1Y Performance:
-20.19%
1-Day Range:
$75.32
$77.00
1-Week Range:
$74.72
$77.62
52-Week Range:
$73.22
$99.20
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
76.55 | 37.26B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
ISRG
Intuitive Surgical Inc
|
448.09 | 158.07B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
193.93 | 55.18B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
282.35 | 41.34B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
267.93 | 19.13B | 2.96B | 487.70M | 344.00M | 6.6758 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
STAAR Surgical Board Defends $1.5 Billion Alcon Acquisition Plan - Finimize
Glass Lewis recommends shareholders vote against STAAR-Alcon deal By Investing.com - Investing.com Nigeria
STAAR urges shareholders to approve Alcon merger despite Glass Lewis report - Investing.com Nigeria
STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company - MSN
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal - GuruFocus
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon De - GuruFocus
STAAR urges shareholders to approve Alcon merger despite Glass Lewis report By Investing.com - Investing.com South Africa
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR - GuruFocus
Broadwood and Glass Lewis urge Staar shareholders to vote "against" sale to Alcon - MarketScreener
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon - The Globe and Mail
Broadwood urges STAAR shareholders to reject Alcon takeover bid - Investing.com
Defender Capital Opposes STAAR Surgical's Proposed Acquisition By Alcon - Nasdaq
Defender Capital Opposes STAAR Surgical?s Sale to Alcon - MarketScreener
Alcon's Proposed Acquisition of STAAR Faces Shareholder Oppositi - GuruFocus
Warner Bros. Challenges Alcon Bid for ‘Matrix’ Studio Rights - Bloomberg Law News
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon - Stock Titan
Yunqi Capital, One Of Staar Surgical Company’S Largest Shareholders, Reiterates Its Opposition To The Proposed Merger With Alcon - TradingView
Yunqi Capital opposes sale of STAAR Surgical to Alcon - Investing.com
Yunqi Capital opposes sale of STAAR Surgical to Alcon By Investing.com - Investing.com Nigeria
Yunqi Capital Challenges Proposed Sale of STAAR to Alcon (ALC) - GuruFocus
Yunqi Capital urges STAAR shareholders to oppose Alcon merger - TipRanks
Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon - FinancialContent
Dry Eye Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AbbVie, Allergan, AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health - Barchart.com
STAAR Surgical Faces Shareholder Clash Over Alcon Buyout - Finimize
How Alcon Inc. Ordinary Shares stock benefits from digital adoptionWeekly Profit Summary & Weekly Momentum Picks - newser.com
Broadwood urges STAAR shareholders to reject $28 per share Alcon deal - Investing.com
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon - FinancialContent
Staar Surgical Co board of directors strongly encourages all stockholders to vote "for" Alcon merger - MarketScreener
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis - Business Wire
How to read the order book for Alcon Inc.Earnings Trend Report & Daily Technical Stock Forecast Reports - newser.com
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgicals Sale to Alcon - MarketScreener
Is Alcon Inc. (2U3) stock inflation resilientMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
What hedge fund moves indicate for Alcon Inc. Ordinary Shares stockPortfolio Update Report & Expert Curated Trade Ideas - newser.com
Momentum divergence signals in Alcon Inc. chartOptions Play & Low Drawdown Investment Ideas - newser.com
Will Alcon Inc. Ordinary Shares stock split increase liquidityPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Swiss Market Settles On Firm Note As Alcon, UBS Group Rise Sharply - Nasdaq
Major STAAR Surgical Investors Push Back On Alcon Acquisition - Finimize
Broadwood urges shareholders to vote against STAAR-Alcon merger By Investing.com - Investing.com Nigeria
Broadwood urges shareholders to vote against STAAR-Alcon merger - Investing.com India
Broadwood PartnersPublishes presentation detailing opposition to Staar Surgical's sale to Alcon - MarketScreener
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon - FinancialContent
Will Alcon Inc. (2U3) stock gain from green policies2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Tools to monitor Alcon Inc. recovery probabilityChart Signals & Precise Entry and Exit Recommendations - newser.com
Fort Worth City Council Approves $6M Incentives for Potential $186M Alcon Expansion - Fort Worth Inc.
Alcon secures incentives for possible Fort Worth factory expansion - WFAA
Alcon, STAAR Surgical Report Expiration of Antitrust Waiting Period for STAAR Acquisition - MarketScreener
Alcon and Staar Surgical announce expiration of Hart-Scott-Rodino waiting period for Alcon's acquisition of Staar - MarketScreener
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR - MarketScreener
$1.5B Eye Care Merger Progresses: Alcon's Premium Buyout of STAAR Surgical Clears Key Regulatory Hurdle - Stock Titan
Stifel Maintains Alcon (ALC) Buy Recommendation - Nasdaq
Broadwood files definitive proxy, STAAR reaffirms Alcon merger - Yahoo Finance
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):